Ignite Creation Date:
2024-05-05 @ 4:54 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00346463
Status:
UNKNOWN
Last Update Posted:
2008-04-28
First Post:
2006-06-29
Brief Title:
Antenatal Allopurinol in Intrauterine Growth Restriction
Sponsor:
UMC Utrecht
Organization:
UMC Utrecht
Study Overview
Official Title:
Does Antenatal Allopurinol Administration Improve Maternal and Neonatal Outcome in Intrauterine Growth Restriction
Status:
UNKNOWN
Status Verified Date:
2006-06
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Growth retardation in utero may be caused by uteroplacental vascular insufficiency When Doppler ultrasound studies of the umbilical artery are abnormal pathological intrauterine growth restriction IUGR can be diagnosed IUGR fetuses have a higher mortality and morbidity both perinatally and on the longer term This is probably due to chronic malnourishment and hypoxia due to placental insufficiency This placental dysfunction causes generation of harmful free oxygen radicals in the fetus The IUGR fetus has a diminished antioxidative capacity which means these free radicals cannot be buffered sufficiently This leads to fetal oxidative stress
Previous studies have shown that allopurinol can inhibit the cascades that lead to generation of free radicals High dosed allopurinol also scavenges radicals and binds free iron without adverse effects on the fetus or mother
As IUGR is associated with placental insufficiency and excessive production of free radicals we hypothesize that antenatal allopurinol administration could lead to a decrease in oxidative stress in the mother and fetus and subsequent improvement of the maternal andor neonatal outcome
Previous studies have shown that allopurinol can inhibit the cascades that lead to generation of free radicals High dosed allopurinol also scavenges radicals and binds free iron without adverse effects on the fetus or mother
As IUGR is associated with placental insufficiency and excessive production of free radicals we hypothesize that antenatal allopurinol administration could lead to a decrease in oxidative stress in the mother and fetus and subsequent improvement of the maternal andor neonatal outcome
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None